Pasithea Therapeutics (KTTA) EBT (2021 - 2026)
Pasithea Therapeutics (KTTA) posted EBT of -$2.9 million for Q1 2026, up 71.62% sequentially from -$10.1 million in Q4 2025, and up 19.47% YoY from -$2.4 million in Q1 2025.
Pasithea Therapeutics (KTTA) EBT (2021 - 2026) Analysis & Trends
Pasithea Therapeutics has reported EBT for 6 years, with the latest figure at -$2.9 million in Q1 2026.
- Quarterly EBT rose 19.47% year-over-year to -$2.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$19.7 million (down 45.03% YoY) and the FY2025 annual result came in at -$20.4 million, down 46.91% from the prior year.
- EBT grew to -$2.9 million in Q1 2026 per KTTA's latest filing, from -$10.1 million in the prior quarter.
- Over five years, EBT peaked at -$1.6 million in Q1 2022 and troughed at -$10.1 million in Q4 2025.
- A 5-year average of -$3.9 million and a median of -$3.6 million in 2023 frame the typical range for EBT.
- The sharpest annual moves came in 2022 and 2024: EBT tumbled 912.15% in 2022, then jumped 36.84% in 2024.
- Over 5 years, EBT stood at -$5.1 million in 2022, then advanced by 1.69% to -$5.0 million in 2023, then surged by 36.84% to -$3.2 million in 2024, then slumped by 218.19% to -$10.1 million in 2025, then jumped by 71.62% to -$2.9 million in 2026.
- According to Business Quant data, EBT over the past three periods registered -$2.9 million, -$10.1 million, and -$3.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 541.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -767.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 312.46 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 177.81 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -11.37 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 81.49 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -264.70 Mn |
| 10 | Pasithea Therapeutics | 15.13 Mn | 15.13 Mn | - | -5.27 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2.87 Mn |
| Dec 31, 2025 | -10.11 Mn |
| Sep 30, 2025 | -3.04 Mn |
| Jun 30, 2025 | -3.72 Mn |
| Mar 31, 2025 | -3.56 Mn |
| Dec 31, 2024 | -3.18 Mn |
| Sep 30, 2024 | -3.00 Mn |
| Jun 30, 2024 | -3.87 Mn |
| Mar 31, 2024 | -3.86 Mn |
| Dec 31, 2023 | -5.03 Mn |
| Sep 30, 2023 | -3.61 Mn |
| Jun 30, 2023 | -3.60 Mn |
| Mar 31, 2023 | -3.27 Mn |
| Dec 31, 2022 | -5.12 Mn |
| Sep 30, 2022 | -4.59 Mn |
| Jun 30, 2022 | -2.66 Mn |
| Mar 31, 2022 | -1.57 Mn |
| Dec 31, 2021 | 630,143.00 |
| Sep 30, 2021 | -1.53 Mn |
| Jun 30, 2021 | -727,947.00 |